Pembrolizumab as a Treatment for PML?

Neurology: Neuroimmunology and NeuroInflammation - United States
doi 10.1212/nxi.0000000000000629
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cutaneous CD56 + T-Cell Lymphoma Developing During Pembrolizumab Treatment for Metastatic Melanoma

JAAD Case Reports
Dermatology
2018English

Is PML a Tumor Suppressor?

Frontiers in Oncology
Cancer ResearchOncology
2013English

PML Degradation: Multiple Ways to Eliminate PML

Frontiers in Oncology
Cancer ResearchOncology
2013English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients With High PD-L1 Expression in Singapore

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2019English

Pembrolizumab-Induced Sarcoid-Like Reactions During Treatment of Metastatic Melanoma

Radiology
Nuclear MedicineRadiologyImaging
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy